All In Biotech

Drug Trial Radar · NCT03386032

8-Week Atopic Dermatitis (AD) Treatment Study

Last checked: Nov 19, 2026Latest source record: Dec 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

65

Actual

Start

Nov 27, 2017

Primary completion

Aug 18, 2018

Study completion Aug 18, 2018

Sponsor

Lead sponsor
Procter and GambleIndustry
Sponsor type
Industry
First posted
Dec 29, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to investigate the clinical effectiveness of the Sponsor's experimental cream treatment on eczema as measured by visual grading of SCORAD (scoring of atopic dermatitis).

Conditions

  • Atopic Dermatitis Eczema

Interventions

  • Investigational OTC CreamDrug

    Investigational Over the Counter (OTC) Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.

  • 0.05% DesonideDrug

    Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions. Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions.

  • Placebo CreamOther

    Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic DermatitisTime frame: Baseline to Week 8
  2. Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Severe Atopic DermatitisTime frame: Baseline to Week 8

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Wake Research, LLC

    Raleigh, North Carolina

  • WR (Wake Research) ClinSearch

    Chattanooga, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.